|
|
|
Volumn 17, Issue 1, 2013, Pages 74-85
|
|
The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
ESTRADIOL;
ESTRADIOL, ESTRIOL DRUG COMBINATION;
ESTRIOL;
INTERLEUKIN 6;
PRASTERONE;
PROGESTERONE;
SEX HORMONE;
TESTOSTERONE;
TRIACYLGLYCEROL;
TUMOR NECROSIS FACTOR ALPHA;
ARTICLE;
BLOOD;
BLOOD PRESSURE;
CLIMACTERIUM;
DRUG COMBINATION;
DRUG EFFECT;
FEMALE;
GLUCOSE BLOOD LEVEL;
HEMOSTASIS;
HORMONE SUBSTITUTION;
HUMAN;
INTRADERMAL DRUG ADMINISTRATION;
MENTAL STRESS;
METABOLISM;
PHYSIOLOGY;
POSTMENOPAUSE;
QUALITY OF LIFE;
TREATMENT OUTCOME;
ADMINISTRATION, CUTANEOUS;
BIOLOGICAL MARKERS;
BLOOD GLUCOSE;
BLOOD PRESSURE;
DEHYDROEPIANDROSTERONE;
DRUG COMBINATIONS;
ESTRADIOL;
ESTRIOL;
FEMALE;
GONADAL STEROID HORMONES;
HEMOSTASIS;
HORMONE REPLACEMENT THERAPY;
HUMANS;
INTERLEUKIN-6;
PERIMENOPAUSE;
POSTMENOPAUSE;
PROGESTERONE;
QUALITY OF LIFE;
STRESS, PSYCHOLOGICAL;
TESTOSTERONE;
TREATMENT OUTCOME;
TRIGLYCERIDES;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 84883777993
PISSN: 10924221
EISSN: None
Source Type: None
DOI: None Document Type: Article |
|
Times cited : (34)
|
|
References (0)
|
